Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.
作者信息
Okwo-Bele Jean-Marie, LaForce F Marc, Borrow Ray, Preziosi Marie-Pierre
机构信息
Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Serum Institute of India, Ltd, Pune.
出版信息
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S389-90. doi: 10.1093/cid/civ592.
Abstract
摘要
相似文献
1
Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S389-90. doi: 10.1093/cid/civ592.
2
A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S387-8. doi: 10.1093/cid/civ490.
3
From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S391-5. doi: 10.1093/cid/civ593.
4
Technical Development of a New Meningococcal Conjugate Vaccine.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S404-9. doi: 10.1093/cid/civ595.
5
Lessons from the Meningitis Vaccine Project.
Viral Immunol. 2018 Mar;31(2):109-113. doi: 10.1089/vim.2017.0120. Epub 2017 Nov 8.
6
Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?
Science. 2010 Dec 10;330(6010):1466-7. doi: 10.1126/science.330.6010.1466.
7
[Africa: towards the eradication of meningitis A?].
Rev Med Suisse. 2011 Jun 22;7(300):1378-9.
8
Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
Hum Vaccin Immunother. 2018 May 4;14(5):1098-1102. doi: 10.1080/21645515.2017.1378841. Epub 2017 Nov 8.
9
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
Vaccine. 2013 Mar 1;31(11):1453-7. doi: 10.1016/j.vaccine.2012.12.035. Epub 2012 Dec 27.
10
Meningococcal carriage in the African meningitis belt.
Trop Med Int Health. 2013 Aug;18(8):968-78. doi: 10.1111/tmi.12125. Epub 2013 May 18.
引用本文的文献
1
Impact of serogroup A meningococcal conjugate vaccine for Africa.
Hum Vaccin Immunother. 2018 May 4;14(5):1116-1117. doi: 10.1080/21645515.2017.1412022. Epub 2018 Jan 16.
2
Meningococcal Vaccinations.
Infect Dis Ther. 2016 Jun;5(2):89-112. doi: 10.1007/s40121-016-0107-0. Epub 2016 Apr 16.
本文引用的文献
1
MenAfriVac as an Antitetanus Vaccine.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S570-7. doi: 10.1093/cid/civ512.
2
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S521-30. doi: 10.1093/cid/civ518.
3
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20. doi: 10.1093/cid/civ672.
4
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S507-13. doi: 10.1093/cid/civ626.
5
The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S489-92. doi: 10.1093/cid/civ625.
6
Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S467-72. doi: 10.1093/cid/civ499.
7
Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S459-66. doi: 10.1093/cid/civ599.
8
Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S428-33. doi: 10.1093/cid/civ491.
Zotero 插件